Foghorn Therapeutics Inc.
FHTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $288.9M
$4.92
▲ +1.03%
P/E
-4.97
Mkt Cap
$288.9M
52-Wk Range
$3.27–$7.61
52-Week Range
$3.27 - $7.61
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 14.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Gene Traffic Control platform enabling systematic discovery of chromatin regulatory dependencies
- First-mover advantage in targeting understudied chromatin regulators with limited competitive landscape
- Strategic partnerships with Merck and Loxo Oncology validating platform and expanding development capabilities
- Focused pipeline addressing high-mortality cancers with significant unmet medical needs
Bear Case
1 risk
- High volatility (beta 2.9). Larger-than-normal price swings expected.
Growth
Mild headwinds expected
Clinical trial progression of FHD-286 in metastatic uveal melanoma and relapsed/refractory AML/MDS
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+32.6% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying FHTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 6, 2026
Reported EPS of -$0.10 vs -$0.25 consensus (+59.2% surprise). Revenue of $16.1M vs $6.8M expected (+136.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+59.2%
Revenue trend · last 8Q
—
-50%
+18%
+10%
+4%
+224%
-45%
+113%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$7.8M
$2.9M
$6.0M
$7.6M
$8.2M
$9.2M
$3.3M
$16.1M
Margins · last 8Q
Gross
100.0%
Operating
-54.8%
Profit
-44.7%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How FHTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related